Sue Washer | President and Chief Executive Officer |
Stephen Potter | Chief Business Officer |
Bill Sullivan | Chief Financial Officer |
Mark Shearman | Chief Scientific Officer |
Joe Pantginis | H.C. Wainwright |
Dae Gon Ha | Stifel |
Kristen Kluska | Cantor Fitzgerald |
Matthew Luchini | BMO Capital |
Yanan Zhu | Wells Fargo |
Zegbeh Jallah | ROTH Capital Partners |
Good afternoon, and welcome to the AGTC Financial Results Conference call for the Third Quarter of Fiscal Year 2021. Today's call is being recorded.
Before we get started, I would like to remind everyone that during this conference call, AGTC may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its current and planned clinical trials. Actual results could differ materially from those discussed in these forward-looking statements. Due to a number of important factors including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic and other risks described in the Risk Factors section of AGTC's most recently filed annual report on Form 10-K and other periodic reports filed with the SEC.